AAAAAA
Results:
1-12
|
Results: 12
Authors:
Vermeer, F
Citation: F. Vermeer, Thrombolytic therapy in patients of female gender, THROMB RES, 103, 2001, pp. S101-S104
Authors:
Ophuis, AJO
Bar, FW
Vermeer, F
Janssen, W
Doevendans, PA
Haest, RJ
Dassen, WR
Wellens, HJJ
Citation: Ajo. Ophuis et al., Angiographic assessment of prospectively determined non-invasive reperfusion indices in acute myocardial infarction, HEART, 84(2), 2000, pp. 164-170
Authors:
Hellemons, B
Langenberg, M
van Ree, J
Knottnerus, A
Lodder, J
Vermeer, F
Schouten, H
Citation: B. Hellemons et al., Using anticoagulation or aspirin to prevent stroke - Reply, BR MED J, 320(7240), 2000, pp. 1010-1011
Authors:
Vermeer, F
Vahanian, A
Fels, PW
Besse, P
Muller, E
Van de Werf, F
Fitzgerald, D
Darius, H
Puel, J
Garrigou, D
Simoons, ML
Citation: F. Vermeer et al., Argatroban and alteplase in patients with acute myocardial infarction: TheARGAMI study, J THROMB TH, 10(3), 2000, pp. 233-240
Authors:
Vermeer, F
Ophuis, AJMO
van der Berg, EJ
Brunninkhuis, LG
Werter, CJ
Boehmer, AG
Lousberg, AH
Dassen, WR
Bar, FW
Citation: F. Vermeer et al., Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study, HEART, 82(4), 1999, pp. 426-431
Authors:
Hellemons, BSP
Langenberg, M
Lodder, J
Vermeer, F
Schouten, HJA
van Ree, JW
Knottnerus, JA
Citation: Bsp. Hellemons et al., Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin, BR MED J, 319(7215), 1999, pp. 958-964
Authors:
Vermeer, F
Bosl, I
Meyer, J
Bar, F
Charbonnier, B
Windeler, J
Barth, H
Citation: F. Vermeer et al., Saruplase is a safe and effective thrombolytic agent; Observations in 1698patients: Results of the PASS study, J THROMB TH, 8(2), 1999, pp. 143-150
Authors:
Hellemons, BSP
Langenberg, M
Lodder, J
Vermeer, F
Schouten, HJA
Lemmens, TGJ
van Ree, JW
Knottnerus, JA
Citation: Bsp. Hellemons et al., Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation: The PATAF trial study design, CONTR CL TR, 20(4), 1999, pp. 386-393
Authors:
Maas, ACP
van Domburg, RT
Deckers, JW
Vermeer, F
Remme, WJ
Kamp, O
Cats, VM
Simoons, ML
Citation: Acp. Maas et al., Sustained benefit at 10-14 years follow-up after thrombolytic therapy in myocardial infarction, EUR HEART J, 20(11), 1999, pp. 819-826
Authors:
Spiecker, M
Windeler, J
Vermeer, F
Michels, R
Seabra-Gomes, R
vom Dahl, J
Kerber, S
Verheugt, FWA
Westerhof, PW
Bar, FW
Nixdorff, U
Barth, H
Hopkins, GR
von Fisenne, MJM
Meyer, J
Citation: M. Spiecker et al., Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: Five-year results of the PRIMI Trial, AM HEART J, 138(3), 1999, pp. 518-524
Authors:
Ophuis, TJMO
Bar, FW
Vermeer, F
Krijne, R
Jansen, W
de Swart, H
van Ommen, V
de Zwaan, C
Engelen, D
Dassen, WR
Wellens, HJJ
Citation: Tjmo. Ophuis et al., Early referral for intentional rescue PTCA after initiation of thrombolytic therapy in patients admitted to a community hospital because of a large acute myocardial infarction, AM HEART J, 137(5), 1999, pp. 846-853
Authors:
Vermeer, F
Citation: F. Vermeer, Mode of action and pharmacology of saruplase, INT J CL PR, 1998, pp. 6-8
Risultati:
1-12
|